It is trading at $37.40 a tad higher than $35.01, the stock’s 50 day moving average and a bit higher than the 200 day moving average of $36.69. The 50 day moving average was up $2.39 or +6.84% and the 200 day average moved up $0.71. Natus Medical Incorporated shares had a trading volume of 341K in the last trading session. Overall, volume was up 28.23% over the stocks normal daily volume.
Investors are feeling more bearish on Natus Medical Incorporated recently at least if you consider the uptick in short interest. The stock had a rise in short interest of 0.28% as of the latest report on May 31, 2017. Short interest grew from 2,039,988 to 2,045,793 over that period. Days to cover decreased -2.8 to 4.9 and the short interest percentage is 0.06% as of May 31.
Here is the rundown on market activity for Natus Medical Incorporated (NASDAQ:BABY). President and CEO James B. Hawkins disclosed the purchase of 4,000 shares of BABY stock. The shares were purchased at an average price of $33.98. The President and CEO now owns $19,641,222 of the stock according to the SEC filing. James B. Hawkins, President and CEO reported the purchase of 6,000 shares of (BABY). The shares were bought on May 31st for an average price of $33.81. Hawkins now owns $19,407,718 of the stock per the Form 4 SEC filing.
Doris Engibous, Director disclosed the sale of 5,000 shares. The shares were sold on May 25th for an average price of $32.68. The Director now owns $576,802 of the stock according to the SEC filing.
Here are a few additional firms who have increased or decreased their stake in (BABY). As of quarter end Fisher Asset Management, LLC had disposed of a total of 9,375 shares trimming its holdings by 1.6%. The value of the company’s investment in Natus Medical Incorporated went from $23,459,000 to $21,944,000 decreasing 6.5% since the last quarter. Clinton Group Inc bolstered its holdings by buying 4,955 shares an increase of 43.6% in the quarter. Clinton Group Inc controls 16,307 shares worth $640,000. The value of the position overall is up by 62.0%.
Creative Planning expanded its position by buying 977 shares an increase of 59.3% from 03/31/2017 to 06/30/2017. Creative Planning now controls 2,624 shares with a value of $98,000. The total value of its holdings increased 50.8%. Bank Of Montreal /can/ added to its stake by buying 796 shares an increase of 331.7%. Bank Of Montreal /can/ currently owns 1,036 shares valued at $39,000. The value of the position overall is up by 333.3%.
On October 4, 2016 Benchmark began coverage giving it an initial rating of “Buy” and setting a price target of $55.00. On September 13 the company was upgraded to “Outperform” from “” in a report from Raymond James.
On April 5 Roth Capital left the stock rating at “Buy” but lowered the price target to $39.00 from $44.00. On October 7 the company was changed to a “Outperform” by William Blair down from the previous “Market Perform” rating.
The company is trading down by -0.66 percent from yesterday’s close. The P/E ratio is currently 35.96 and the market cap of the company is 1.21B. As of the latest earnings report the EPS was $1.04 and is projected to be $1.70 for the current year with 32,485,000 shares now outstanding. Next quarter’s EPS is estimated at $0.41 with next year’s EPS projected to be $2.02.
Natus Medical Incorporated, launched on July 20, 2000, is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Business’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics..